Skip to main content
November 18, 2014
Newly formed company has licensed Caribou technology to advance CRISPR-Cas9 for therapeutic development

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced the launch of Intellia Therapeutics, a new company created by Caribou and Atlas Venture. Intellia will utilize Caribou’s proprietary CRISPR-Cas9 gene editing and repair technology platform in the development of new therapies targeting a variety of genetic-based diseases.